MiNK Therapeutics, Inc. (INKT) Dividend History

Company News

• MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

  MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present interim data from its ongoing Phase 2 study testing AgenT-797 in combination with Agenus' botensilimab and balstilimab in patients with refractory gastric cancer.

  GlobeNewswire Inc.

  Featured Companies: AGEN
• MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

  MiNK Therapeutics presented data on a Phase 2 trial evaluating a combination of its iNKT cell therapy, Agenus' botensilimab and balstilimab, and standard chemotherapy in advanced gastroesophageal cancer patients. The novel combination demonstrated signals of tolerability and activity in this patient population.

  GlobeNewswire Inc.

  Featured Companies: AGEN
• MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

  NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

  GlobeNewswire Inc.
• MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

  NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS.

  GlobeNewswire Inc.
• MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

  NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has entered into a stock purchase agreement to sell securities in a private placement financing (PIPE) for $5.8 million. This capital injection is earmarked for accelerating the clinical trials of MiNK-215, our leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein (FAP) in solid tumors, which is planned to enter the clinic in early 2025.

  GlobeNewswire Inc.